Avedro, Inc. is a medical technology company that specializes in developing and commercializing tools for vision-correcting procedures. Their products are aimed at correcting various eye disorders including nearsightedness, farsightedness, and astigmatism. The company has gained widespread recognition due to the development of their patented corneal cross-linking technology which can halt or delay the progression of keratoconus, a progressive eye disorder that causes a cone-like shape to develop on the cornea. Uses: The primary use of Avedro, Inc.'s products is in vision-correction procedures. They offer a range of FDA-approved products that are used to correct myopia, hyperopia, astigmatism, and presbyopia. One of the most high-profile products developed by this company is their corneal cross-linking technology. This technology is used to lock the collagen fibers in place within the cornea and halt or slow the progression of keratoconus, which is a prevalent cause of corneal transplantations. The procedure is also used to treat corneal ectasia, which is also a condition characterized by a weakened cornea. Dosage: The dosage of Avedro, Inc.'s products varies depending on the specific procedure involved. For corneal cross-linking, the procedure usually requires a unique riboflavin solution which is applied to the cornea after which UV light exposure is done. The riboflavin is a vital component in the procedure as it facilitates the cross-linking of the collagen fibers within the cornea. Appropriate dosage is determined by the ophthalmologist in consultation with the patient based on age, medical history, and the type of procedure involved. Side Effects: Like any other medical procedure, Avedro, Inc. products have associated side effects. The most common side effects relate to corneal exposure to UV light, a component required in corneal cross-linking. Patients may experience a burning or itching sensation in the eyes following the procedure, and there may be a risk of corneal infection. However, such side effects are generally mild to moderate in severity and are known to subside within a few days. Interactions: Avedro, Inc. products may interact with medications that affect corneal health such as some topical eye medications or contact lenses. It is essential to get your ophthalmologist's guidance regarding any interactions your medications may have before undergoing any Avedro, Inc. procedure. Patients who have undergone any corneal surgery may need to be guided regarding the best course of action for their particular situation. Generic: Avedro, Inc. products utilize a patented combination of ultraviolet light and riboflavin in corneal cross-linking. This technology is unique to the company and is marketed under the brand name Photrexa® Viscous, Photrexa® and the KXL® system. Therefore, there are no generic versions of Avedro, Inc. products, as Photrexa® and the KXL® system are proprietary to the company. Demographics: Avedro, Inc. products are approved for use on patients in the United States and Europe. The FDA has approved Photrexa® Viscous, Photrexa® and the KXL® system for use in the United States in 2016. The procedure is particularly suited for patients with keratoconus or corneal ectasia, and there is no age restriction for the procedure. However, for younger patients, the best outcomes are reported when the procedure is done early on in the disease progression. Avedro, Inc. products are usually administered in an ophthalmologist's clinic and require close post-procedure monitoring to ensure there are no complications. Conclusion: Avedro, Inc. is a medical technology company that has developed patented corneal cross-linking technology used to correct vision problems and halt or slow the progression of keratoconus. The treatment involves the use of Photrexa® Viscous, Photrexa®, and the KXL® system, all proprietary to the company. The procedure is generally safe and effective, and the side effects, although minimal, are usually temporary and subside quickly, with appropriate care. Avedro, Inc. products have gained FDA approval and are used in ophthalmology clinics in the United States and Europe. However, as with any other medical procedure, it is essential to undergo a consultation with your ophthalmologist to tailor your care specifically to your needs and to be sure of the benefits and risks of the procedure.